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Consort 2010 statement: extension to cluster
randomised trials
The Consolidated Standards of Reporting Trials (CONSORT) statement was developed to improve
the reporting of randomised controlled trials. It was initially published in 1996 and focused on the
reporting of parallel group randomised controlled trials. The statement was revised in 2001, with a
further update in 2010. A separate CONSORT statement for the reporting of abstracts was published
in 2008. In earlier papers we considered the implications of the 2001 version of the CONSORT
statement for the reporting of cluster randomised trial. In this paper we provide updated and extended
guidance, based on the 2010 version of the CONSORT statement and the 2008 CONSORT statement
for the reporting of abstracts.
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Many journals now require that reports of trials conform to the
guidelines in the Consolidated Standards of Reporting Trials
(CONSORT) statement, first published in 1996,1 revised in
2001,2 and revised most recently in 2010.3 The statement
includes a checklist of items that should be included in the trial
report. These items are evidence based whenever possible and
are regularly reviewed.4 The statement also recommends
including a flow diagram to show the progression of participants
from group assignment through to the final analysis. An
explanation and elaboration of the rationale for the checklist
items is provided in an accompanying article.4
The standard CONSORT statement focuses on reporting parallel
group randomised controlled trials in which individual
participants are randomly assigned to study groups. However,
in some situations it is preferable to randomly assign groups of
people (such as communities, families, or medical practices)
rather than individuals. Reasons include the threat of
“contamination” (the unintentional spill-over of intervention
effects from one treatment group to another) of some
interventions if individual randomisation is used.5 6 Also, in
certain settings, randomisation by groupmay be the only feasible
method of conducting a trial.7 Trials with this design are
variously known as field trials, community based trials, group
randomised trials, place based trials, or (as in this paper) cluster
randomised trials.8Although wewould recommend the standard
use of the term “cluster randomised trial” we recognise that
those searching electronically for cluster trials may need to
expand their search strategy to ensure that cluster trials using
the terms “community” or “group” randomised trials are
included.
In earlier papers we considered the implications of the
CONSORT statement for the reporting of cluster randomised
trials.9 10 Here we present updated guidance, based on the 2010
revision of the CONSORT statement,3 and the 2008 CONSORT
extension for the reporting of abstracts.11 12
Scope of this paper
Cluster randomised trials are characterised by their multilevel
nature; most often cluster trials involve two levels—the cluster
and their individual members, such as general practice and
patient—although trials of more than two levels, such as
hospital-ward-patient, do exist. In this paper we focus on two
level cluster trials for simplicity and refer to the groups that are
randomised as “clusters” (these could be families, wards, etc)
and we refer to the individual members of the clusters as
“participants” (as they are usually individual people) unless
there is ambiguity in a particular context. On occasion, however,
a single person may be a cluster, with their teeth or eyes or limbs
or multiple lesions as the members of the cluster. Measurements
of these teeth, eyes, etc, within one individual will be correlated
and so should not be treated as independent observations. A
particular context for such trials is split mouth trials in
dentistry.13 However, those studies have additional
considerations relating to the randomisation and the comparisons
being within individuals. We do not consider them in detail in
this paper.
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In some situations another form of clustering can be observed
in individually randomised trials—for example, several patients
receiving care from the same therapist or surgeon.14 This type
of clustering is also not the focus of this paper—it is discussed
in the CONSORT extension for non-pharmacological
treatments.15 Nor are we interested in trials with one cluster per
intervention. Trials with one cluster per arm should be avoided
as they cannot give a valid analysis, as the intervention effect
is completely confounded with the cluster effect.16 It has been
recommended that the minimum number of clusters per arm to
ensure a valid analysis should be at least four.17 Sometimes trials
are inappropriately referred to as using cluster
randomisation—for example, “To avoid patient interference a
cluster randomisation was performed to alternate months.”18
This study was in fact not truly randomised nor was it a cluster
trial. However, there is a particular design within the scope of
cluster randomised trials, the cluster randomised crossover trial,
where each participating cluster receives both intervention and
control treatments consecutively, in separate periods, but the
order of treatment is randomised.19 Similarly, many stepped
wedge designs, which randomise in terms of the period for
receipt of the intervention, may be seen as a type of cluster
crossover trial if the unit of randomisation is a cluster.20 21
We note that cluster randomised trials have no connection to
cluster analysis; an exploratory multivariate statistical technique
used to define clusters of similar people. We also note that the
statistical issues raised by cluster randomised trials are different
to those raised by cluster sampling, in which natural clusters
such as geographical areas are identified and some clusters are
chosen to be studied (for example, as in Mucklebecker 2006),22
preferably at random.
In summary, our focus is on trials that are cluster randomised
by design and have two or more clusters per intervention arm.
Updating the CONSORT statement for
cluster randomised trials
The updated CONSORT 2010 statement includes a 25 item
checklist. The wording was simplified and clarified and the
specificity of certain elements of the statement made more
explicit, for example by breaking some items into sub-items.
Methodological advances reported in the literature since the
2001 statement were also reviewed and taken into account where
appropriate.
To ensure that the extension for cluster trials reflected the
wording of the updated CONSORT statement, and to integrate
any important advances in the methodology for cluster trials
since 2004, we decided to update the cluster extension in the
summer of 2010.
The updating process
To identify papers relevant to the methodology for cluster
randomised trials published between 2004 and 2010, we
undertook an electronic search of Medline, Embase, and the
Cochrane Methodology Register and a full text search of
Statistics in Medicine, Clinical Trials, Contemporary Clinical
Trials, and BMC Medical Research Methodology. The search
yielded 1198 abstracts. One researcher (MKC) initially assessed
the abstracts for relevance and classified 155 as potentially
relevant to the update of the CONSORT extension. Each author
took primary responsibility for aggregating and synthesising
evidence most relevant to the reporting of a trial in particular
areas—for example, analysis, intracluster correlation
coefficients. We also reviewed all correspondence that had been
received after the publication of the 2004 extension for cluster
trials. We decided to reformat the checklist for cluster trials in
line with the style currently promoted by the CONSORTGroup,
as used, for example, in the extensions for non-pharmacological
interventions15 and pragmatic trials.23 In this updated style,
additions to the main CONSORT checklist items are presented
in a separate column rather than being integrated directly into
the text of the checklist.
The researchers met face to face and by teleconference on
several occasions to discuss updating the checklist and revision
of the text, with additional discussion in conference calls and
by email. A draft revised paper was distributed to the larger
CONSORT Group for feedback. After consideration of their
comments a final version of the extension was prepared and
approved by the CONSORT executive.
Box 1 presents the noteworthy changes from the 2004 cluster
extension paper. As for previous CONSORT checklists, we
have included only those items deemed fundamental to the
reporting of a cluster randomised controlled trial—that is,
providing a minimum standard for the reporting of cluster trials.
Moreover, a few items may be crucial to a trial but not included,
such as approval by an institutional ethical review board,
because funding bodies strictly enforce ethical review and
medical journals usually address reporting ethical review in
their instructions for authors. It is also not the purpose of this
paper to provide a best practice guide on the design, conduct,
and analysis of cluster randomised trials—these issues have
been outlined by several other authors.
Advances in methodology since 2004
The 2004 extension paper10 outlined the principal implications
of adopting a cluster randomised trial (summarised in box 2).
These included the need to account for the non-independence
of participants within clusters and the need to be explicit about
the level of inference at which the trial interventions and trial
outcomes are targeted. Since 2004 there have been several
methodological advances in the specialty. Detailed overviews
of these methodological developments are presented
elsewhere.17 24-27
Advances in reporting requirements since
2004
In 2008 the CONSORT Group also produced a separate
reporting checklist for abstracts of reports of randomised
controlled trials,11 12which presented a minimum list of essential
items that should be reported within a trial abstract. The
motivation for the extension for the reporting of abstracts was
multi-fold but it was clear that readers of journals often base
their assessment of a trial on the information presented in the
abstract and as such quality reporting was particularly important
within this aspect of the trial report. Therefore as part of the
update process for the reporting of cluster trials we also reviewed
the CONSORT extension for abstracts and highlighted the key
areas where cluster trial specific reporting requirements would
apply.
Quality of reporting of cluster trials
Early surveys of published cluster trials found that the conduct
and reporting of the trials were often poor.5 27-33 One study,
however, found clear signs of improvement in the methods and
reporting of cluster trials published in the BMJ from 1983 to
2003.34
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Box 1: Noteworthy changes from CONSORT 2004 extension for cluster randomised trials
• Separate presentation of the standard CONSORT checklist items and extension specific to cluster trials (table 1⇓)
• Provision of updated examples of good reporting practice
• Provision of an augmented checklist for abstracts of cluster randomised controlled trials
• Expansion of item 7a (sample size) to include the possibility of unequal cluster sizes
• Discussion of CONSORT 2010 item 7b (interim analysis guidelines) included in the context of cluster randomised controlled trials
• Item 10 (generation of random allocation sequence for participants) replaced by items 10a, 10b, and 10c
Box 2: Methodological considerations in cluster randomised trials
Design
• Observations on participants in the same cluster tend to be correlated (non-independent), so the effective sample size is less than that suggested by
the actual number of individual participants. The reduction in effective sample size depends on average cluster size and the degree of correlation within
clusters, ρ, also known as the intracluster (or intraclass) correlation coefficient (ICC).
• The intracluster correlation coefficient is the proportion of the total variance of the outcome that can be explained by the variation between clusters. A
related coefficient of variation, k, between clusters has also been described.90 Although no simple relation exists between k and ρ for continuous
outcomes, another study described the relation for binary outcomes.91 For both types of variable, when k=0, ρ also=0. Unlike k, the intracluster correlation
coefficient cannot be defined for time to event data.
• Adjusting for the intracluster correlation is necessary for a valid analysis, but it reduces statistical power. For the same statistical power the overall
sample size needs to be larger in a cluster randomised trial than in an individually randomised trial.
• If m is the cluster size (assumed to be the same for all clusters), then the inflation factor, or “design effect,” associated with cluster randomisation is
1+(m−1)ρ. Although typically ρ is small (often <0.05) and it is often not known when a trial is planned (and only estimated with error after a trial is
completed), its impact on the inflation factor can be considerable if the clusters are large. In general, the power is increased more easily by increasing
the number of clusters rather than the cluster size.
• Cluster randomised trials may use a simple, completely randomised design, a matched cluster design, or a stratified design. If an appropriate matching
factor is used, the matched design gains power relative to the completely randomised design. However, such matching variables may be difficult to
identify, especially if the number of clusters to be matched is large. In addition, calculating the intracluster correlation coefficient from a matched design
is generally problematic because the variation between clusters cannot be disentangled from the effects of the intervention or interventions and the
matching factors.8 The use of stratified designs is therefore generally preferable.92
Conduct
• The conduct of cluster randomised controlled trials differs in some ways from that of trials that randomise individuals. In particular, random allocation
is done at the cluster level. Clusters are usually randomised all at once (or in batches) rather than one at a time, as in most individually randomised
trials. This feature of the cluster randomised trial facilitates the use of a matched design.
• Sometimes consent can be sought both at cluster level and at individual participant level before randomisation. Commonly, however, prior consent to
randomisation by individual cluster participants is not feasible.93 In such circumstances, once clusters have been randomly assigned, participants in
the clusters can no longer be asked for their consent to be randomised to receive either of the interventions, only for consent to receive the intervention
to which their group has been assigned, and for consent to follow-up. This introduces the possibility of post-randomisation selection bias5 94 as well as
ethical concerns,95-97 which have been explored in qualitative studies.98 These concerns are analogous to those arising from randomised consent
designs99-101 for individually randomised trials.
• The concept of what blinding means in the context of a cluster randomised controlled trial is also complex—some patients may know which intervention
they are allocated to but not that they are in a trial.
Analysis
• Cluster randomised controlled trials also present special requirements for analysis.102 If the inference is intended at the participant level, they should
not be analysed as if the trial was individually randomised as, if ρ is greater than zero, this gives spurious precision.
• The data could be analysed as if each cluster was a single individual, but this approach ignores the information collected on participants within a cluster
and hence may not use the full richness of the dataset. Advances in software for the analysis of cluster randomised controlled trials have been reviewed.24
• Bayesian approaches to the analysis of cluster randomised trials have also been developed.103-105
• For in depth discussion of survival analysis that links to k, see Hayes and Moulton.17
Interpretation
• The interpretation of the results from cluster randomised trials may be more complicated than individually randomised trials as the conclusions may
relate to the clusters, to the participants in those clusters, or to both.
Recent reviews have shown that deficiencies in reports of cluster
trials remain common.35-42 For example, the unit of analysis error
(where results were analysed without accounting for the
clustering) was seen in 19/40 (48%) of medical care trials,35 and
among 75 reports of cluster trials in cancer prevention and
control a third (34%) “failed to report any analyses that were
judged to be appropriate.”37 Among 50 reports of cluster trials
of screening interventions, 32 (64%) reported using a method
of analysis that took account of clustering, but in several the
method used was not stated explicitly.40 Those authors found
that reporting was much better in high influence journals.
Three recent reviews have considered reporting in relation to
the CONSORT extension for cluster trials. The first of these
reviews examined the reports of 106 cluster randomised trials
in children, published from 2004 to 2010.41 Issues specific to
cluster trials were poorly reported. The rationale for using a
cluster design was given in 32% of the articles; how clustering
was accounted for in sample size calculation and in analysis
were reported in 59% and 65% of trials; and 55% of flow
diagrams (which were included in 80% of the articles) omitted
some information on the numbers of participants or clusters.
Overall, 37% of the articles reported an intracluster correlation
coefficient. The second review examined 300 randomly sampled
cluster randomised trials published during 2000-08.42 Of those
presenting sample size calculations, 60% accounted for
clustering in the design, whereas 70% accounted for clustering
in analysis. Only 18% of the articles reported an intracluster
correlation coefficient. Both of these studies saw only a slight
improvement in reporting over time, but the third review
suggested the opposite.40
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In summary, there is some evidence for improved reporting of
cluster randomised trials but the quality of reporting remains
well below an acceptable level.
Extension of CONSORT 2010 to cluster
trials
Table 1 presents the revised checklist for the reporting of a
cluster randomised controlled trial (updated in line with
CONSORT 2010). Some items are extended to cover the
reporting requirements relating to the cluster design, and item
10 is replaced by items 10a, 10b, and 10c, acknowledging the
added complexity imposed on the randomisation and recruitment
by the cluster design. Items requiring an extension from the
CONSORT 2010 statement, and those items particularly relevant
to the reporting of cluster randomised trials, are explained, with
illustrative examples. As all our examples have been taken from
previously published papers, it is inevitable that several do not
display all the desirable elements of good reporting. Where this
is the case, or where there might be ambiguity, we have
attempted to identify which specific aspects of reporting are
addressed.
We reviewed the checklist for abstracts and provide an
augmented checklist for reporting of abstracts within cluster
randomised controlled trials in table 2⇓.
Title and abstract
Item 1a
Standard CONSORT item: identification as a randomised
trial in the title
Extension for cluster trials: identification as a cluster
randomised trial in the title
Example
Cluster randomised trial of a targeted multifactorial
intervention to prevent falls among older people in hospital43
Explanation
The primary reason for identifying the design in the title is to
ensure appropriate indexing of the study as a cluster randomised
trial in Medline. This indexing ensures ease of identification of
these studies for inclusion in systematic reviews. “Community”
randomised and “group” randomised are also widely used
descriptions for such trials (for example, the trial report by
Cavalcante et al)44, especially when entire communities are
randomised. A recent review of cluster randomised trials showed
that identification of cluster randomised trials remains
problematic, with only 48% of cluster randomised controlled
trials published in 78 journals between 2000 and 2007 being
clearly identified as cluster randomised in titles or abstracts.45
Identification of the trial as a cluster randomised trial also
ensures that readers will not be misled by apparently large
sample sizes.
Item 1b
Standard CONSORT item: structured summary of trial
design, methods, results, and conclusions (for specific
guidance see CONSORT for abstracts)11 12
Extension for cluster trials: outlined in table 2
Example: presented in figure 1⇓
Explanation
In 2008 a CONSORT extension on reporting abstracts was
published.11 12 We have provided an augmented checklist for
this aspect of trial reporting in this update (table 2). As the
extension on reporting abstracts was published only recently,
and the 2004 extension to cluster trials did not specifically deal
with abstracts, we were not able to find examples of good
reporting tackling all the items required. We have therefore
developed an abstract based on enhancing a published abstract
(fig 1). Although this increases the word count by over a third,
many journals now follow PubMed in no longer setting a limit.
In addition to the items recommended for all trials it is important
that abstracts for cluster randomised controlled trials give the
number of clusters per arm (and numbers of participants) and
the level of inference (that is, the level at which hypotheses and





Standard CONSORT item: scientific background and
explanation of rationale
Extension for cluster trials: rationale for using cluster design
Example 1
Our intention was to enhance the application of evidence by
the whole labour ward team so, to minimise contamination,
the unit of randomisation and analysis was the obstetric unit46
Example 2
A cluster randomization was chosen for practical reasons
and to prevent contamination by preference of patient or
physician (selection bias)47
Explanation
Under the principles of the Helsinki declaration it is unethical
to expose people unnecessarily to the risks of research.48Because
a cluster randomised design increases the complexity of the
research and usually requires more participants than an
individually randomised design (to ensure equivalent statistical
power), it is particularly important that the rationale for adopting
a cluster design is outlined in the introduction.49 In a recent
review of cluster randomised trials, the reviewers50 found that
a third of published cluster trials could have used individual
randomisation instead. As such, it is important that all
alternatives are considered and that if a cluster trial is adopted
it is clear why it was judged to be the most appropriate and
robust design to adopt.51
Item 2b
Standard CONSORT item: specific objectives or hypotheses
Extension for cluster trials: whether objectives pertain to
cluster level, individual participant level, or both
Example
The main aim of the present study is to use the rigour of a
RCT [randomised controlled trial] in an evaluation
comparing the effects of different approaches to knowledge
transfer on policy and practice in the care of preterm babies
in another setting . . . The main outcomes were at the level
of unit policy and practice [neonatal units were the clusters]52
Explanation
Descriptions of specific objectives and hypotheses need to make
it clear whether they pertain to the individual participant level,
the cluster level, or both. When objectives and hypotheses are
targeted at the cluster level, analysis and interpretation of results
at the cluster level might be appropriate. When the objectives
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and hypotheses are targeted at the individual participant level,
statistical techniques at the individual level are usually required.
Methods
The main difference when reporting a cluster trial, as opposed
to an individually randomised trial, is that there are two levels
of inference rather than one: the cluster level and the individual
participant level.53 Thus, to allow readers to interpret the results
appropriately, it is important to indicate explicitly the level at
which the interventions were targeted, hypotheses generated,
randomisation done, and outcomes measured.
Trial design
Item 3a
Standard CONSORT item: description of trial design (such
as parallel, factorial) including allocation ratio
Extension for cluster trials: definition of cluster and
description of how design features apply to clusters
Example 1 (definition of clusters)
Clusters were health centers with more than 400 residents
aged 65.0-67.9 y in low-middle socioeconomic status
municipalities (average population 127,000 individuals) in
the Santiago Metropolitan area54
Example 2 (description of how the design applied to clusters)
This study was a pragmatic, cluster randomised, factorial,
controlled trial. A 2×2 factorial design was used to assess
the effect of each intervention and to explore the effect of
the interventions combined . . . The four allocated groups
were general practitioners’ [the cluster] use of C reactive
protein testing (1), training in enhanced communication skills
(2), the interventions combined (3), and usual care (4)55
Example 3 (definition of how the design applied to clusters)
Hospitals [the clusters] were matched by country, type of
hospital (public, private or social security), and baseline
caesarean section rate (15-20%, 21-35%, or >35%), and the
paired units were randomly assigned to intervention or
control56
Explanation
The cluster is the unit of randomisation and it should be
appropriately defined so that it can be adequately taken into
account in the analysis. Whether the cluster randomised design
is parallel, matched pair, or other, and whether the treatments
have a factorial structure, has implications for the appropriate
analysis of the outcome data and thus should be reported.
Random assignment generally ensures that any baseline
differences in group characteristics are the result of chance
rather than of some systematic bias.57 In individually randomised
trials the sample size can be sufficiently large to ensure balanced
baseline characteristics across groups. In cluster randomised
designs, if the number of clusters is large, simple randomisation
may often be sufficient.8 This is not usually the case for these
designs, however, because the number of clusters to be
randomised is often small. Even if cluster specific characteristics
are balanced (that is, characteristics of the randomly allocated
clusters), researchers have little control over the participants
within each cluster (this is the case whether the number of
clusters is large or small).8 As a result, some form of constraint
(matching or stratification) is often imposed on randomisation
in a cluster randomised design in an attempt to increase precision
and minimise imbalance across treatment groups (see also item
8b). Any constraint imposed on the cluster randomised trial
affects the sample size and the analysis and thus should be
reported.
Item 3b
Standard CONSORT item: important changes to methods
after trial commencement (such as eligibility criteria), with
reasons
Example
Concerns that lower than expected pneumonia incidence
rates would affect the trial’s ability to detect an effect of
nutritional supplementation on pneumonia incidence resulted
in a protocol amendment 4 months into the study. A further
12 health centers were approached to join the study, eight
of which were subsequently randomly assigned … to either
the nutritional supplement intervention alone arm (n=4) or
the control arm (n=4)54
Explanation
In cluster randomised controlled trials, as in any trial, important
changes may have occurred to the study methods after the
original protocol was written. Knowing about these changes
and the reasons for them can aid interpretation, especially if
there may be suspicions of bias. Changes that affect the number




Standard CONSORT item: eligibility criteria for participants
Extension for cluster trials: eligibility criteria for clusters
Example
The study comprised 41 practices in Wessex . . . Inclusion
criteria were ≥4medical partners; list size >7000; a diabetes
register with >1% of practice population; and a diabetes
service registered with the health authority . . . Nurses
reported all new cases of diabetes to the trial office. Willing
patients aged 30-70 were included in the trial. Patients were
excluded if they were private patients, housebound, mentally
ill, had severe learning difficulties, or were subsequently
found to have been diagnosed previously with, or not to have,
diabetes, or were found to have type 1 diabetes58
Explanation
In cluster randomised trials two sets of eligibility criteria are
considered—the eligibility of the clusters (for example, the
general practices) to be included in the trial and the eligibility
of individual participants (for example, the eligible patients
within each general practice) to be included in clusters. As such,
both sets of eligibility criteria need to be reported.
Interventions
Item 5
Standard CONSORT item: the interventions for each group
with sufficient details to allow replication, including how
and when they were actually administered
Extension for cluster trials:whether interventions pertain to
cluster level, individual participant level, or both
Example 1 (intervention at individual participant level)
In the intervention group [consisting of seven sectors or
clusters] the windows of all 241 houses [units of observation
within sectors] (with a total of 1336 inhabitants) were
covered with loosely hanging polyester curtains impregnated
with the pyrethroid insecticide . . . In the 222 houses in six
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of the control sectors [clusters] the windows were covered
with non-impregnated curtains and in one randomly selected
control sector [cluster] with 106 houses no curtains were
provided59
Example 2 (intervention at cluster and individual participant
level)
See example in box 3.60
Example 3 (intervention at cluster level)
The purpose of this study is to evaluate the effect of
randomizing GP practices to prescribing feedback using
academic detailing (postal bulletin plus an educational
outreach visit) compared to postal bulletin alone on
prescribing of cardiovascular preventive therapies in patients
with CVD or diabetes . . . The postal bulletins contained
individualized GP prescribing feedback and educational
information based on the 2003 European guidelines on CVD
prevention. . . . The feedback was displayed using graphs
and included the actual number of GP-registered patients
not receiving recommended therapy61
Explanation
It is important to describe whether the intervention was targeted
at the cluster level or the individual participant level. The level
of inference is not necessarily the same as the level at which
the intervention is applied, although inference at the cluster




Standard CONSORT item: completely defined pre-specified
primary and secondary outcome measures, including how
and when they were assessed
Extension for cluster trials: whether outcome measures
pertain to cluster level, individual participant level, or both
Example 1 (outcome at level of cluster)
The purpose of this study is to evaluate the effect of
randomizing GP practices to prescribing feedback using
academic detailing (postal bulletin plus an educational
outreach visit) compared to postal bulletin alone on
prescribing [at the cluster level] of cardiovascular preventive
therapies in patients with CVD or diabetes61
Example 2 (outcome at level of individual participant rather
than cluster)
We evaluated the effect of a computer based clinical decision
support system and cardiovascular risk chart [both targeted
at physicians—at the cluster level] on patient centred
outcomes of absolute cardiovascular risk and blood pressure62
Example 3 (outcomes at cluster level and individual
participant level)
Primary outcomes were chosen for their ability to assess
effectiveness and quality of service and included number of
visits, referrals fromRHC [rural health centres] for antenatal,
intrapartum or postpartum problems [cluster level outcomes],
place of delivery and low birthweight infant (<2500 g)
[individual level outcomes]. The secondary outcomes were
antenatal diagnosis of hypertension and twin pregnancy,
perinatal mortality, operative delivery, preterm delivery (<37
weeks) [individual level outcomes] and the proportion of
visits at which fundal height measurement was recorded and
plotted on the antenatal record in the new model [cluster
level outcome]63
Explanation
Whether an intervention is evaluated at the cluster level or
individual participant level has implications for the appropriate
analysis of the outcome data. It is therefore important that the




Standard CONSORT item: how sample size was determined
Extension for cluster trials: method of calculation, number
of clusters, cluster size(s) (and whether equal or unequal
cluster sizes are assumed), a coefficient of intracluster
correlation (ICC or k), and an indication of its uncertainty
Example 1
We calculated sample size with a method that takes into
account the intracluster correlation coefficient, the number
of events, the expected effect, and the power of the study.
We assumed an intracluster correlation of ρ=0.2, a minimum
of 25 patients for each practice, and a worst case control rate
of 50%. Under these assumptions we anticipated a power of
87% to detect a difference of 15% in rates between the two
groups with α=0.05 with 60 practices for each intervention
group64
Example 2
The calculation of the sample size . . . was based on 0.6%
detection of CIN grade 2+ using the conventional Pap test
and an expected 33% increase using liquid-based cytology
with an α of 0.05 and β of 0.20, an intraclass correlation
coefficient of 0.05, an average cluster size of 250, and a
standard deviation of 200. This resulted in a coefficient of
variation [k] of 0.8 and design effect of 1.59. By
multiplication of the design effect by sample size without
cluster effect, a sample size of 44 947 women in each group
was obtained47
Explanation
A principal difference between the planning of a cluster
randomised trial and that of an individually randomised trial is
the calculation of the sample size. To retain equivalent power
to an individually randomised trial, the number of individuals
in a cluster randomised trial needs to be increased.When clusters
are of similar size, the key determinants of the increase required
(which can be substantial) are the intracluster correlation
coefficient and the average cluster size (see box 2 for formula).
Sample size calculations when cluster sizes are unequal are
discussed elsewhere.65 Reports of cluster randomised trials
should state the assumptions used when calculating the number
of clusters and the cluster sample size.
The power of the trial can also be decreased by imbalances in
cluster sizes at recruitment and by differences in the intracluster
correlation coefficient across clusters.66Differences in expected
recruitment across clusters should be reported, since sample
size calculations usually assume equal cluster sizes.
Item 7b
Standard CONSORT item: when applicable, explanation of
any interim analyses and stopping guidelines
Example
These calculations conservatively included a 10% design
effect, which was expected to be negligible in view of the
small cluster size and rare outcome. The data monitoring
and ethics committee did conditional power calculations in
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e5661 doi: 10.1136/bmj.e5661 (Published 4 September 2012) Page 6 of 21
RESEARCH METHODS & REPORTING
Box 3: Example of precise details of intervention at cluster and individual level from Murphy et al60
Tailored practice care
• An action plan for each practice was agreed with the practice and regularly reviewed by the study research nurse and practice
• The study nurse maintained regular contact with the practices
• The practice received a two page study newsletter every four months
Academic detailing
• An academic general practitioner (one per centre) made one 90 minute educational outreach visit to each intervention practice to
promote drug prescribing guidelines for secondary prevention through interactive case based scenarios
• A study research nurse (one per centre) delivered another 90 minute session on behaviour change, which was intended to facilitate
reflection on change to patient lifestyle and, through role play, new techniques to be used by the practice
Tailored patient care
• At the first intervention consultation, the patient and practitioner together identified areas of management that could be improved and
the patient was invited to prioritise one particular aspect of his or her lifestyle for change
• Possible ways of achieving targets reflecting optimal management were identified and action plans individualised so that small, realistic
goals for change were agreed
• A booklet containing information on all the key risk factors for coronary heart disease was used by practitioners in discussions on
initial target setting and then given to the patients
Regular consultations
Patients were invited for an appointment with the general practitioner or nurse every four months; targets and goals for optimal secondary
prevention were reviewed at each visit
2003 and recommended that the trial be continued until
October 200867
Explanation
As in many individually randomised trials, there may be a need
for an independent body, such as a data monitoring
committee,68 69 to monitor accumulating data to protect patients
in the trial and future patients. The main principles of interim
analysis remain the same for cluster randomisation as for
individual randomisation,70 and the interim analysis would
probably use the same statistical methods that were planned for
the final analysis of a cluster randomised trial. Few cluster
randomised trials seem to have explicit stopping boundaries,
however, and cluster randomised controlled trials may need
some additional considerations. For instance, if more
information becomes available about the assumptions on which
the original power calculations were based, or if clusters are
recruited over a period of time, an interim analysis after, for
example, 25% of the person time has been completed, may not
provide as much as 25% of the information due to the expected
variation between clusters17; a particular amount of person time





Standard CONSORT item: type of randomisation; details of
any restriction (such as blocking and block size)
Extension for cluster trials: details of stratification or
matching if used
Example 1 (stratification)
Neonatal units were stratified by designation of level of care
within the managed Clinical Neonatal Networks (n=25) and
by level of care delivered (level I, II or III), and then ordered
alphabetically by name of hospital and imported into
statistical computer software Stata V.9 at the London School
of Hygiene and Tropical Medicine. The programme
generated a series of blocks of varying size (two, four or six)
for each stratum and allocated units to control or active
intervention randomly within each block52
Example 2 (stratification)
The allocation schedule for random assignment of care
models to clinics was computer generated, including
stratification by study site and clinic characteristics, at a
central location (WHO, Geneva, Switzerland) by the
Statistical Unit of the UNDP/UNFPA/WHO/World Bank
Special Programme of Research, Development, and Research
Training in Human Reproduction72
Example 3 (matching)
We . . . paired the 14 [urban sectors of Trujillo, Venezuela]
according to the incidence of cutaneous leishmaniasis in the
12 months before the baseline household survey. For each
of the seven pairs we randomly allocated one sector (using
computer created random numbers) . . . to the intervention
group and the other to the control group59
Explanation
The way in which the randomisation sequence is generated
depends on the design: if the number of clusters is large, a
completely (cluster) randomised design may be a convenient
option and then simple randomisation might be sufficient.8
Otherwise, restricted randomisation may be useful. For a
stratified design (for example, stratification by centre), the
sequence is generated independently within each stratum. In
addition, to control the probability of obtaining an allocation
sequence with an undesirable sample size imbalance in the
intervention groups, the randomisation within strata can be
restricted. Common techniques for restricted randomisation
include permuted blocks and the random allocation rule (that
is, a single permuted block).73 The random allocation rule is
useful when all clusters are available at the time of generating
the sequence, which is often the case. Using (more than one)
random permuted blocks is more common for individually
randomised designs, in which participants arrive sequentially.
For the specific form of stratification of two clusters per stratum
(a matched paired design), the sequence should allocate the two
interventions at random to the clusters within pairs.
Allocation concealment mechanism
Item 9
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Standard CONSORT item: mechanism used to implement
the random allocation sequence (such as sequentially
numbered containers), describing any steps taken to conceal
sequence until interventions were assigned
Extension for cluster trials: specification that allocation was
based on clusters rather than individuals and whether
allocation concealment (if any) was at cluster level,
individual participant level, or both
Example (allocation was based on clusters and concealed
at cluster level)
The treatment allocation for each site was kept in Geneva
until the site had completed the basic introductory training
of study personnel (both in standard-model and
control-model clinics [clusters]). When local investigators
were ready to implement the training workshops for the staff
if the clinic were assigned the new model, the study
statistician sent the treatment allocation by facsimile directly
to the principal investigator of the selected site72
Explanation
In individually randomised trials, adequate concealment of the
treatment allocation is crucial for minimising potential bias. If
the person recruiting participants has foreknowledge of the
allocation, bias can result.74 In a cluster randomised trial,
allocation of treatment is predetermined for each member of
the cluster. Hence the potential for selection bias (selective
inclusion of patients into the trial) within clusters is particularly
high.5 6 It is therefore important that authors outline any
strategies that were implemented to minimise the possibility of
selection bias—for example, whether clusters were identified
and recruited before randomisation, whether allocation was
concealed from the person or people who provided access to
the cluster or provided permission for the cluster to be included
in the trial (for example, the cluster “guardian” or
“gatekeeper”)75, whether all patients within a cluster were
included or, if not, whether recruitment of patients was by a
person masked to the cluster allocation. Allocation concealment




Standard CONSORT item: who generated the random
allocation sequence, who enrolled participants, and who
assigned participants to interventions
Extension to cluster trials: replaced by items 10a, 10b, and
10c
Item 10a
Extension for cluster trials: who generated the random
allocation sequence, who enrolled clusters, and who assigned
clusters to interventions
Example 1 (enrolment of clusters and method of assignment)
Rural primary schools with 150 children or more, and over
15 children per class were eligible for inclusion. . . .Meetings
were held in participating schools to explain the nature and
purpose of the trial to parents or legal guardians, and written
informed consent was obtained. Schoolchildren with parental
consent and no history of adverse reaction to sulfa-based
drugs were eligible for recruitment. . . . We stratified schools
into three groups according to school examination
performance in previous years . . . Ten schools were
randomly selected from each school-performance stratum,
and within each stratum schools were randomly allocated to
one of six coded drug groups by use of block randomisation
.. . according to a computer-generated random number list
by an investigator . . . blind to drug group76
Example 2 (who generated sequence and who assigned
clusters to interventions)
We conducted the trial in a contiguous area encompassing
most of Ward 29 and all of Ward 30 in Eastern Kolkata, a
legally registered urban slum with a population of about
60,000 residents. Before vaccination, a census of the
population enumerated all households and persons in the
study area and characterized the socioeconomic status, water
source, and hygiene status of each household. Each
household and person in the census were assigned a unique
study identification number. The census, together with
geographic mapping, was used to define 80 contiguous
geographic clusters that served as the units of randomization.
. . . The clusters were stratified according to ward and the
number of residents who were 18 years of age or younger
(<200 vs. ≥200 persons) and the number of residents who
were older than 18 years (<500 vs. ≥500 persons), resulting
in eight strata. For each stratum, a statistician who was
unaware of the study-group assignments used a table of
random numbers to assign half the 80 clusters to each
vaccine77
Explanation
As outlined in the original CONSORT explanatory paper78 it is
important that all the steps of the random allocation process
from generation to implementation are adequately described.
Within cluster randomised trials the randomisation process has
the added complexity of having two levels involved in the
allocation process—the inclusion and allocation of clusters and
the inclusion of cluster members. As such, the implementation
processes adopted for each step need to be outlined separately.
Item 10b
Extension for cluster trials:mechanism by which individual
participants were included in clusters for the purposes of the
trial (such as complete enumeration, random sampling)
Example 1
The family practices associated with the 2 study sites served
as the units of randomization. . . . Family practices associated
with the clinical study sites were randomly assigned to the
liquid-based cytology or the conventional Pap test group.
All women screened at 1 of the participating family practices
were included in the study47
Example 2
All cluster residents were eligible to receive a study vaccine
if they were 24months of age or older, had no reported fever
or had an axillary temperature of no more than 37.5°C at the
time of administration, and were not pregnant or lactating.
All subjects or their guardians provided written informed
consent77
Example 3
Twenty seven practices agreed to participate in the trial: 10
were therefore randomly allocated to each of the two
intervention arms and seven to the usual care arm. To ensure
sufficient numbers of patients with adequate follow up data,
30 patients were randomly sampled from each practice62
Explanation
A previous study5 showed that selection bias can arise in cluster
randomised controlled trials, especially at the point when
participants are selected from within clusters. This bias can be
reduced by complete enumeration and inclusion of all
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participants identified as eligible or, if a sample from the cluster
is required, by having a third party make the selection or
blinding the person identifying participants until after assessment
of eligibility.
Item 10c
Extension for cluster trial: from whom consent was sought
(representatives of cluster, or individual participants, or both),
and whether consent was sought before or after
randomisation
Example 1 (who provided consent)
Because outcome data were routinely collected at hospitals
and no personal identifiers were transmitted, all the
institutional review boards waived the requirement for
individual consent. Responsible authorities from all the
hospitals provided written consent, and birth attendants also
provided written consent56
Example 2 (consent process and when consent sought)
There were 12 antenatal-care clinics in each of three study
sites and 17 in the fourth site that were eligible for the study
and where the health authorities agreed to let the clinics be
included in the trial . . . [cluster-level consent]. The
[individual level] informed consent procedure was based on
the single-consent design proposed by Zelen. Thus, informed
consent was requested only from women attending the
antenatal clinics assigned to the new model; women who
refused were cared for according to the standard practice in
their clinic. However, such women were counted in the
intention-to-treat analysis as being assigned to the new-model
group.Women attending the standard-model clinics received
the protocols recommended in each country, in the best
format offered in these clinics . . . 72
Explanation
Many reports of cluster trials do not indicate at which level
consent was sought or its timing in relation to randomisation,
which can lead to bias.79 For example, if consent is sought at
the cluster level post-randomisation but from the active arm
only, there may be differential attrition of whole clusters. Even
if consent is sought from all clusters, attrition bias can arise if
consent to treatment or provision of data is sought from
individual cluster members in the active arm only (see also item
5 and box 2). This reinforces the need to be able to report flow
of patients within clusters over the course of the trial (see item
13).
Specific details of how interventions were administered should
be described, because there are implications for consent and for
adherence. When the intervention is applied at the cluster level
(such as mass media advertising), it may not be feasible to obtain
consent pre-randomisation from individual cluster
members—that is, consent to randomise may have to be sought
at cluster level only. Likewise, consent to intervention may have
to be sought at the cluster level as individual cluster members
may not be able to decline the intervention. Consent will often
be sought at both the cluster level (for example, from the
“gatekeeper”) and from individual cluster members to contribute
data. The specific issues around informed consent in cluster
trials have been considered elsewhere.80 (See also item 10b.)
Blinding
Item 11a
Standard CONSORT item: if done, who was blinded after
assignment to interventions (for example, participants, care
providers, those assessing outcomes) and how
Example
To prevent selective assessment bias, study
personnel—gynecologists, pathologists, cytotechnologists,
and others—involved in the follow-up and review of
histology and cytology were blinded to the cytology
screening system used. . . . A panel of 4 experienced
pathologists who were blinded to the cytological system, the
original cytological and histological findings, and all
follow-up data reviewed the histology47
Explanation
In individually randomised trials the importance of blinding is
well recognised, as a lack of blinding can lead to the inflation
of study effects.74 78 For individually randomised trials it is
therefore recommended that participants and outcome assessors
should be blindedwherever possible to the intervention received.
In cluster trials, however, the concept of blinding is more
complicated. Often the delivery of interventions in cluster trials
involves a range of different people (for example, trainers
training health professionals in the use of guidelines; health
professionals implementing the guidelines for individual
patients; outcome assessors who could be trainers; health
professionals, patients, or a completely different group) at the
different cluster levels and it is often unclear from trial reports
who was and was not blinded within the trial.36 42 It is further
recognised that many cluster trials are pragmatic by nature, as
they are often designed to evaluate changes in service provision
or interventions to change practitioners’ or patients’ behaviour
in real world settings. In such circumstances it is widely
acknowledged that blinding of the intervention is often not
possible (although blinding of those assessing outcome may
still be possible). If this is the case, however, it is important that
it is explicitly acknowledged in the trial report—the CONSORT
statement for pragmatic trials recommends that if blinding was
not done, or was not possible, an explanation as to why should
be included in the text.23
Statistical methods
Item 12a
Standard CONSORT item: statistical methods used to
compare groups for primary and secondary outcomes
Extension for cluster trials: how clustering was taken into
account
Example 1
Because we randomised obstetric units . . . we analysed rates
of marker clinical practices by obstetric units46
Example 2
The primary outcome was expressed as the mean rate
difference between groups (with 95% CI). This value was
measured as the difference between matched hospitals
(intervention hospital minus control hospital) in caesarean
section rate change (caesarean section rate in the intervention
period minus caesarean section rate in the baseline period)
. . . A one-sample two sided t test was used to assess whether
the mean rate difference between groups was statistically
different from zero56
Example 3
We used cluster specific methods because practices rather
than patients were randomised, andwe expected that variance
in how patients were managed would be partly explained by
the practice. Because some patients had more than one
consultation, we added a third level to the analysis to account
for the likelihood that variance in what was done at each
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consultation would be partly explained by the patient . . . 81
[This article also included a box to explain the three level
logistical hierarchical model used.]
Explanation
Identification of the level of inference allows readers to evaluate
the methods of analysis. For example, if the inference was
targeted at the cluster level (at general practitioners rather than
patients, for example) and outcomes were aggregated at the
cluster level, sophisticated cluster adjusted analyses are not
needed (as in examples 1 and 2). However, if the cluster sizes
are unequal, weighting may be recommended because the
variance of the cluster summary statistics is not constant. If the
inference was targeted at the individual patient level, the analysis




Standard CONSORT item: for each group, the numbers of
participants who were randomly assigned, received intended
treatment, and were analysed for primary outcome
Extension for cluster trials: for each group, the numbers of
clusters that were randomly assigned, received intended
treatment, and were analysed for primary outcome
Item 13b
Standard CONSORT item: for each group, losses and
exclusions after randomisation, together with reasons
Extension for cluster trials: for each group, losses and
exclusions for both clusters and individual participants
Examples: presented in figures 2⇓ and 3⇓
Explanation
The flow diagram is a key element of the CONSORT statement
and has been widely adopted. For cluster trials it is important
to understand the flow of clusters as well as the flow of
participants (fig 2). The potential for differential adherence and
follow up is exacerbated in the cluster randomised design
because there are two levels at which drop-outs can
occur—whole clusters or individual participants in a cluster. It
is therefore important to describe the flow of both clusters and
participants when reporting a cluster randomised trial; this
information is essential to interpret the study appropriately.
Although we recommend a flow diagram for communicating
the flow of clusters and participants throughout the study (fig
2), the exact form and content should vary in relation to the
specific features of a trial.We previously presented three options
for modifying the CONSORT flow diagram for presenting
clustered data—presenting the flow of data based only on
clusters, only on individual participants, or on both.9 Further
experience suggests that the type of diagram should depend on
the type of analysis because different approaches to analysis
require information at different levels of the clustered design.
For example, if the analysis is aggregated at the level of the
cluster, the flow diagram should relate to the data at cluster
level. To allow meaningful interpretation, the diagram also
needs to include a measure of the cluster size (and an indication
of how variable cluster sizes are). If, however, the analysis is
multilevel or hierarchical, the flow diagram should present data
flow for both clusters and individual participants.
Baseline data
Item 15
Standard CONSORT item: a table showing baseline
demographic and clinical characteristics for each group
Extension for cluster trials: baseline characteristics for cluster
and individual participant levels as applicable for each group
Example: presented in table 3⇓
Explanation
Random assignment by individual ensures that any differences
in group characteristics at baseline are the result of chance rather
than some systematic bias.74 For cluster randomised trials,
however, the risk of chance imbalance is greater as clusters
rather than individuals are randomised and the number of
clusters is often small (although imbalances can occur even
when the number of clusters is not limited).66 It is therefore
important to present summary baseline information for both




Standard CONSORT item: for each group, number of
participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
Extension for cluster trials: for each group, number of
clusters included in each analysis
Example: presented in figure 4⇓
Explanation
The number of participants who contribute to the analysis of a
trial is essential to interpreting the results. However, not all
participants may contribute to the analysis of each outcome. In
a cluster trial this fact is compounded by the possibility that not
all clusters may contribute to a particular analysis. Because the
sample size calculation and hence the power of the study is
calculated on the assumption that all participants and (especially)
all clusters will provide information, the number of participants
and clusters contributing to a particular analysis should be




Standard CONSORT item: for each primary and secondary
outcome, results for each group, and estimated effect size
and its precision (such as 95% confidence interval)
Extension for cluster trials: results at cluster or individual
participant level as applicable and a coefficient of intracluster
correlation (ICC or k) for each primary outcome
Example: presented in table 4⇓
Explanation
When reporting the results of a cluster randomised trial, point
estimates with confidence intervals should be reported for
primary outcomes. Given the impact of the extent of the
intracluster correlation on the power of the study, the intracluster
correlation coefficient or k statistic for each primary outcome
being analysed should also be provided to assess the magnitude
of the clustering for each outcome (however, if a cluster level
analysis is being undertaken, the concept of the intracluster
correlation is less relevant as each cluster provides a single data
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point). In some situations, especially if it is believed the
intervention will significantly affect the intracluster correlation
coefficient, publishing the intracluster correlation coefficient
from both the control and the intervention arm may be useful.
This information, together with the cluster size or the design
effect, allows readers to assess the appropriateness of the original
sample size calculations. Showing both adjusted and unadjusted
estimates for clustering would provide another indication of the
extent of the clustering. Several authors have published observed
study intracluster correlation coefficients to help with the




Standard CONSORT item: generalisability (external validity,
applicability) of trial findings
Extension for cluster trials: generalisability to clusters or
individual participants (as relevant)
Example (at the cluster level)
Although our trial was completed successfully from both a
methodological and practical point of view, our results may
not be generalisable. The 21 participating practices tended
to be large, with good nursing support, and may have been
particularly committed to improving their quality of care . .
. Furthermore, the observed intervention effect would
probably have been greater if the trial had not taken place
in the context of a health authority audit initiative relating
to patients with coronary heart disease, backed by a financial
incentive87
Explanation
In the discussion section of any trial report, the external validity
of the results should be considered. External validity is more
complicated for cluster randomised trials because the results
may be generalisable to the clusters, to the participants in those
clusters, or to both, and thus the level at which external validity
is addressed should be identified.
Comment
Reports of randomised controlled trials should include key
information on the methods and findings to allow readers to
accurately interpret the results. This information is particularly
important for meta-analysts attempting to extract data from such
reports. The CONSORT 2010 statement provides the latest
recommendations from the CONSORTGroup on essential items
to be included in the report of a randomised controlled trial. In
this paper we introduce and explain corresponding updates in
an extension of the CONSORT checklist specific to reporting
cluster randomised trials.
Use of the CONSORT statement for the reporting of two group
parallel trials is associated with improved reporting quality.88
We believe that the routine use of this proposed extension to
the CONSORT statement will eventually result in similar
improvements to cluster trials.
When reporting a cluster randomised trial, authors should
address all 25 items on the CONSORT checklist using this
document in conjunction with the main CONSORT guidelines.3
Depending on the type of trial done, authors may also find it
useful to consult the CONSORT extensions for
non-pharmacological treatments15 and non-inferiority trials.89
The CONSORT statement can help researchers designing trials
in the future and can guide peer reviewers and editors in their
evaluation ofmanuscripts.Many journals recommend adherence
to the CONSORT recommendations in their instructions to
authors.We encourage them to direct authors to this and to other
extensions of CONSORT for specific trial designs. The most
up to date versions of all CONSORT recommendations can be
found at www.consort-statement.org.
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Tables
Table 1| CONSORT 2010 checklist of information to include when reporting a cluster randomised trial
Page
No*Extension for cluster designsStandard checklist itemSection/topic and item No
Title and abstract
Identification as a cluster randomised trial in the titleIdentification as a randomised trial in the title1a
See table 2Structured summary of trial design, methods, results, and conclusions




Rationale for using a cluster designScientific background and explanation of rationale2a
Whether objectives pertain to the cluster level, the
individual participant level, or both
Specific objectives or hypotheses2b
Methods
Trial design:
Definition of cluster and description of how the design
features apply to the clusters
Description of trial design (such as parallel, factorial) including
allocation ratio
3a
Important changes to methods after trial commencement (such as
eligibility criteria), with reasons
3b
Participants:
Eligibility criteria for clustersEligibility criteria for participants4a
Settings and locations where the data were collected4b
Interventions:
Whether interventions pertain to the cluster level, the
individual participant level, or both
The interventions for each group with sufficient details to allow
replication, including how and when they were actually administered
5
Outcomes:
Whether outcome measures pertain to the cluster
level, the individual participant level, or both
Completely defined prespecified primary and secondary outcome
measures, including how and when they were assessed
6a




Method of calculation, number of clusters(s) (and
whether equal or unequal cluster sizes are assumed),
cluster size, a coefficient of intracluster correlation
(ICC or k), and an indication of its uncertainty
How sample size was determined7a





Method used to generate the random allocation sequence8a





Specification that allocation was based on clusters
rather than individuals and whether allocation
concealment (if any) was at the cluster level, the
individual participant level, or both
Mechanism used to implement the random allocation sequence
(such as sequentially numbered containers), describing any steps
taken to conceal the sequence until interventions were assigned
9
Implementation:
Replaced by 10a, 10b, and 10cWho generated the random allocation sequence, who enrolled
participants, and who assigned participants to interventions
10
Who generated the random allocation sequence, who
enrolled clusters, and who assigned clusters to
interventions
10a
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Table 1 (continued)
Page
No*Extension for cluster designsStandard checklist itemSection/topic and item No
Mechanism by which individual participants were
included in clusters for the purposes of the trial (such
as complete enumeration, random sampling)
10b
From whom consent was sought (representatives of
the cluster, or individual cluster members, or both)




If done, who was blinded after assignment to interventions (for
example, participants, care providers, those assessing outcomes)
and how
11a
If relevant, description of the similarity of interventions11b
Statistical methods:
How clustering was taken into accountStatistical methods used to compare groups for primary and
secondary outcomes
12a




Participant flow (a diagram is
strongly recommended):
For each group, the numbers of clusters that were
randomly assigned, received intended treatment, and
were analysed for the primary outcome
For each group, the numbers of participants who were randomly
assigned, received intended treatment, and were analysed for the
primary outcome
13a
For each group, losses and exclusions for both
clusters and individual cluster members




Dates defining the periods of recruitment and follow-up14a
Why the trial ended or was stopped14b
Baseline data:
Baseline characteristics for the individual and cluster
levels as applicable for each group




For each group, number of clusters included in each
analysis
For each group, number of participants (denominator) included in




Results at the individual or cluster level as applicable
and a coefficient of intracluster correlation (ICC or k)
for each primary outcome
For each primary and secondary outcome, results for each group,
and the estimated effect size and its precision (such as 95%
confidence interval)
17a
For binary outcomes, presentation of both absolute and relative
effect sizes is recommended
17b
Ancillary analyses:
Results of any other analyses performed, including subgroup




All important harms or unintended effects in each group (for specific




Trial limitations, addressing sources of potential bias, imprecision,
and, if relevant, multiplicity of analyses
20
Generalisability:
Generalisability to clusters and/or individual
participants (as relevant)
Generalisability (external validity, applicability) of the trial findings21
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Table 1 (continued)
Page
No*Extension for cluster designsStandard checklist itemSection/topic and item No
Interpretation:
Interpretation consistent with results, balancing benefits and harms,




Registration number and name of trial registry23
Protocol:
Where the full trial protocol can be accessed, if available24
Funding:
Sources of funding and other support (such as supply of drugs), role
of funders
25
*Page numbers optional depending on journal requirements.
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Table 2| Extension of CONSORT for abstracts11 12 to reports of cluster randomised trials
Extension for cluster trialsStandard checklist itemItem
Identification of study as cluster randomisedIdentification of study as randomisedTitle
Description of the trial design (for example, parallel, cluster, non-inferiority)Trial design
Methods:
Eligibility criteria for clustersEligibility criteria for participants and the settings where the data were
collected
Participants
Interventions intended for each groupInterventions
Whether objective or hypothesis pertains to the cluster level,
the individual participant level, or both
Specific objective or hypothesisObjective
Whether the primary outcome pertains to the cluster level,
the individual participant level or both
Clearly defined primary outcome for this reportOutcome
How clusters were allocated to interventionsHow participants were allocated to interventionsRandomisation
Whether or not participants, care givers, and those assessing the outcomes
were blinded to group assignment
Blinding (masking)
Results:
Number of clusters randomised to each groupNumber of participants randomised to each groupNumbers randomised
Trial status*Recruitment
Number of clusters analysed in each groupNumber of participants analysed in each groupNumbers analysed
Results at the cluster or individual level as applicable for each
primary outcome
For the primary outcome, a result for each group and the estimated effect
size and its precision
Outcome
Important adverse events or side effectsHarms
General interpretation of the resultsConclusions
Registration number and name of trial registerTrial registration
Source of fundingFunding
*Relevant to conference abstracts.
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Table 3| Example of baseline information for each group given at individual and cluster levels (adapted from Sur et al).77 Values at individual
level are numbers (percentages) and at cluster level are means (standard deviations) unless stated otherwise
Hepatitis A vaccine (n=18 804)Vi vaccine (n=18 869)Variables
Individual level
27.9 (17.8)28.5 (18.0)Mean (SD) age (years)
9920 (53)9876 (52)Male
10 825 (58)12 335 (65)Hindu
7.0(3.7)7.1(3.9)Mean (SD) No of members of household
13 099 (70)13 980 (74)Head of household able to read and write
7636 (41)7795 (41)Monthly household per capita expenditure above median of 500 rupees
3918 (21)4131 (22)At least one luxury item owned in household
1824 (10)2711 (14)Tube-well or faucet as source of drinking water in household
577 (3)905 (5)Flush toilet in household
18 429 (98)18 547 (98)Access to specific place for waste disposal in household
9935 (53)8900 (47)Household farther from treatment centre than median distance
Cluster level
Age groups (No/cluster):
273 (115)256 (118)2-18 years
500 (93)503 (84)>18 years
28.5 (4.6)29.0 (5.0)All residents per cluster (years)
146 (36)142 (27)Households (No/cluster)
470 (104)472 (103)Vaccinated participants (No/cluster)
1.38 (1.38)1.54 (1.40)Cases of typhoid fever during year before study (No/1000 cluster residents)
22.2 (20.1)18.4 (17.8)Population density (No of residents/100m2/cluster)
60 (12)61 (11)Percent vaccine coverage of people ≥2 year of age
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Table 4| Example of study including data on numbers analysed by cluster and intracluster correlation coefficients (adapted from Feder et
al)107
P valueAdjusted χ2 statistic
Adjusted odds ratio (95%
CI)
Intracluster correlation
coefficientNo (%) in control group





<0.00112.24.0 (1.9 to 8.2)0.01332/83 (39)54/81 (67)Cholesterol
<0.0110.53.0 (1.5 to 35.8)0.09832/154 (21)74/169 (44)Weight
<0.056.22.4 (1.2 to 4.7)0.05322/154 (14)46/169 (27)Diet
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Figures
Fig 1 Example of abstract for report of cluster randomised trial
Fig 2 Recommended format for flow diagram of progress of clusters and individuals through phases of randomised trial
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Fig 3 Example of flow diagram for cluster trial (adapted from Siebers et al47)
Fig 4 Example of flow of clusters from recruitment to analysis (reproduced from Francis et al)108
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